ArticleBMC microbiology2026
Isolation, characterization, and genomic analysis of novel bacteriophage AEV23 against multidrug-resistant Klebsiella pneumoniae isolated from Cystic Fibrosis patients.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKlebsiella pneumoniae is a well-known opportunistic pathogen in humans and can cause chronic obstructive pulmonary disease (COPD) in Cystic Fibrosis (CF) patients. This pathogen has developed resistance to β-lactam antibiotics due to the expression of extended-spectrum beta-lactamase (ESBL) genes, leading to current treatment challenges in these patients. Bacteriophages are alternative and effective treatment options against multidrug-resistant (MDR) pathogens. In this study, a lytic bacteriophage was isolated from untreated sewage, tested against multidrug-resistant K. pneumoniae strains, and evaluated for its therapeutic potential in vitro.
methodsThis study presents the microbiological, physicochemical, and genomic characterization of a virulent bacteriophage. The phage was studied by electron microscopy, host range analysis, multiplicity of infection (MOI) determination, adsorption rate measurement, burst size calculation, latent period assessment, stability testing to temperature, chloroform, pH and salt stress, and biofilm removal ability evaluation demonstrated by SEM; the bacteriophage genome was studied by complete genome sequencing.
resultsThe phage exhibited a broad and highly specific host range for K. pneumoniae strains. Its stability under stress conditions, including changes in temperature, pH, salt concentration, and exposure to chloroform, was 64.63%, 52.79%, 68.36%, and 98.92%, respectively. The one-step growth curve results demonstrated that the bacteriophage had a latent period of 30 min and a burst size of approximately 98 plaque-forming units per infected cell (PFU/cell). Adsorption assays revealed that 92% of isolated phages adsorbed to bacterial cells within 5 min. Additionally, the bacteriophage showed inhibitory activity against bacterial growth at an MOI 1. The biofilm removal assay demonstrated that the phage eliminated over 93% of the cellular biomass, as confirmed by scanning electron microscopy (SEM). Whole-genome analysis showed that it belongs to the Loughboroughvirus genus. The phage has a linear, double-stranded DNA genome with a length of 55,637 bp and a GC content of 45.9%. The genome encodes 76 open reading frames (ORFs), including structural proteins, DNA metabolism enzymes, lysis modules, and packaging proteins. No tRNAs, lysogenic genes, or virulence factors were detected in the genome.
conclusionsCharacterization of phage VB_KpM-AEV23 demonstrated its high host specificity against K. pneumoniae, making it a suitable candidate for phage therapy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.